Person:
NARTER, SELİN

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

NARTER

First Name

SELİN

Name

Filters

2019 - 201912020 - 20222
Reset filters

Settings

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Publication
    Malignant transformation of monostotic fibrous dysplasia into angiosarcoma in the proximal tibia
    (Wolters Kluwer Medknow Publications, 2021-04-01) Yalçınkaya, Ulviye; YALÇINKAYA, ÜLVİYE; Narter, Selin; NARTER, SELİN; Bilgen, Muhammet S.; BİLGEN, MÜHAMMET SADIK; Yazıcı, Zeynep; YAZICI, ZEYNEP; Tıp Fakültesi; Ortopedi Ana Bilim Dalı
    The majority of bone angiosarcomas are primary tumors while secondary angiosarcomas arise after radiation therapy or bone infarctus. This article presents a case of malignant transformation of monostotic fibrous dysplasia into angiosarcoma. An 80-year-old female presented with pain on right cruris. Radiological examination revealed a lesion with lytic areas and destruction of cortical bone on right tibia. Gross and histopathological examination showed two areas with an abrupt transition. The solid component was composed of curved, immature bony trabeculae in a fibroblastic stroma. The other component involved epitheloid cells forming slit-like vascular spaces. The diagnosis of angiosarcoma and fibrous dysplasia was given. Malignant transformation of fibrous dysplasia into angiosarcoma is extremely rare; as this is the sixth case in the existing literature. Prognosis of fibrous dysplasia is generally good and less than 1% of the patients develop a malignant tumor. Therefore, patients with fibrous dysplasia should be offered a life-long follow-up.
  • No Thumbnail Available
    Publication
    A close look at our cases with parathyroidectomy: 11 years of experience
    (Edizioni Minerva Medica, 2022-06-01) Saraydaroğlu, Özlem; SARAYDAROĞLU, ÖZLEM; ÖZŞEN, MİNE; Kirdak, Turkay; Narter, Selin; NARTER, SELİN; Ertürk, Erdinç; ERTÜRK, ERDİNÇ; Tıp Fakültesi; Patoloji Ana Bilim Dalı; 0000-0002-5771-7649; AAJ-6536-2021
    BACKGROUND: Hyperparathyroidism is caused by parathyroid adenoma, hyperplasia or carcinoma. Parathyroid ade-nomas are the most common cause of parathyroid disease (85-88%) while atypical parathyroid adenomas and carcinomas are the least frequently seen parathyroid neoplasms which cause diagnostic difficulty. This series aims to identifiy lesions of parathyroidectomy specimens in our center and draw attention to borderline cases in between parathyroid adenoma and carcinoma.METHODS: The study included 638 parathyroidectomy materials diagnosed in our center between the years 2005 and 2016 and examined retrospectively, and all were included in the study.RESULTS: In all the 638 parathyroidectomy cases evaluated, 427 were diagnosed with adenoma, 117 with hyperplasia, 54 with normal parathyroid tissue, 32 with parathyroid neoplasm with uncertain malignant potential, 7 with parathyroid carcinoma and 1 with normal thyroid tissue.CONCLUSIONS: Parathyroid neoplasm with uncertain malignant potential defines cases with suspicious histopathological features of carcinoma but doesn't meet the criteria for parathyroid carcinoma. In our series, these cases are identified as atypical parathyroid adenoma. We present clinical and morphological features of our parathyroidectomy cases in an 11-year period and aim to raise concern about borderline cases in between adenoma and carcinoma. We think that such tumors, similar to the thyroid neoplasm classification, should be defined as parathyroid neoplasms with uncertain malignant potential and should be followed closely.
  • No Thumbnail Available
    Publication
    Dynamic contrast-enhanced T1-weighted perfusion magnetic resonance imaging identifies glioblastoma immunohistochemical biomarkers via tumoral and peritumoral approach: A pilot study
    (Elsevier Science, 2019-04-09) Öztürk, Kerem; Soylu, Esra; Tolunay, Şahsine; Narter, Selin; Hakyemez, Bahattin; Özturk, Kerem; Soylu, Esra; TOLUNAY, ŞAHSİNE; NARTER, SELİN; HAKYEMEZ, BAHATTİN; Tıp Fakültesi; Radyoloji Ana Bilim Dalı; 0000-0001-9664-2347; 0000-0002-3425-0740; AAI-2318-2021; E-1228-2018; AAI-1612-2021; DSW-1175-2022; FOL-7699-2022
    OBJECTIVE: We aimed to evaluate the usefulness of dynamic contrast-enhanced T1-weighted perfusion magnetic resonance imaging (DCE-pMRI) to predict certain immunohistochemical (IHC) biomarkers of glioblastoma (GB) in this pilot study.METHODS: We retrospectively reviewed 36 patients (male/female, 25:11; mean age, 53 years; age range, 29-85 years) who had pretreatment DCE-pMRI with IHC analysis of their excised GBs. Regions of interest of the enhancing tumor (ER) and nonenhancing peritumoral region (NER) were used to calculate DCE-pMRI parameters of volume transfer constant, back flux constant, volume of the extravascular extracellular space, initial area under enhancement curve, and maximum slope. IHC biomarkers including Ki-67 labeling index, epidermal growth factor receptor (EGFR), oligodendrocyte transcription factor 2 (OLIG2), isocitrate dehydrogenase 1 (IDH1), and p53 mutation status were determined. The imaging metrics of GB with IHC markers were compared using the Kruskal-Wallis test and Spearman correlation analysis.RESULTS: Among 30 patients with available IDH1 status, 14 patients (46.6%) had IDH1 mutation. EGFR amplification was present in 24/36 (66.6%) patients. Mean Ki-67 labeling index was 29% (range, 1.5%-80%). p53 mutation was present in 20/36 GBs (55%), whereas OLIG2 expression was positive in 29/36 GBs (80.5%). Various DCE-pMRI parameters gathered from the ER and NER were significantly correlated with IDH1 mutation, EGFR amplification, and OLIG2 expression (P < 0.05). Ki-67 labeling index showed a strong positive correlation with initial area under enhancement curve (r = 0.619; P < 0.001).CONCLUSIONS: DCE-pMRI could determine surrogate IHC biomarkers in GB via tumoral and peritumoral approach, potential targets for individualized treatment protocols.